^
4ms
Myriad Genetics and Personalis partner to market solutions to pharma customers (Personalis Press Release)
"Myriad Genetics, Inc...and Personalis, Inc...announced a non-exclusive collaboration through which Myriad will market the Personalis®ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners who use the MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests."
Licensing / partnership
|
BRACAnalysis CDx™ • Myriad myChoice® CDx • Myriad myRisk® Hereditary Cancer
7ms
Myriad Genetics and Onsite Women’s Health partner to help more women understand breast cancer risk (Myriad Genetics Press Release)
"Myriad Genetics, Inc...and Onsite Women’s Health, a leading national provider of breast health services...announced the launch of a new breast cancer risk assessment program to help more women understand their breast cancer risk."
Licensing / partnership
|
Myriad myRisk® Hereditary Cancer
8ms
Myriad Genetics Announces Inclusion of Breast Density to MyRisk with RiskScore Breast Cancer Risk Assessment (GlobeNewswire)
"Myriad Genetics, Inc...announced its MyRisk® Hereditary Cancer Test with RiskScore® now incorporates breast density using Tyrer-Cuzick version 8 (TCv8) to provide patients and providers with a more comprehensive look at their five-year and remaining lifetime risk for breast cancer....The Federal Drug Administration recently updated mammography regulations requiring mammography facilities to notify patients about the density of their breasts by September 2024."
Clinical
|
Myriad myRisk® Hereditary Cancer
12ms
Myriad Genetics and SimonMed Imaging collaborate to advance precision medicine with new genetic risk assessment program (Myriad Genetics Press Release)
"Myriad Genetics, Inc...and SimonMed Imaging, one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, today announced the planned launch of a new hereditary cancer assessment program that combines diagnostic imaging, genetic risk assessment utilizing MyRisk® with RiskScore® and patient education."
Licensing / partnership
|
Myriad myRisk® Hereditary Cancer
over1year
Myriad Genetics patient outcomes study shows RiskScore leads to more accurate breast cancer risk prediction than standard-of-care risk model (Myriad Genetics Press Release)
"Myriad Genetics, Inc...presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a standard-of-care risk assessment alone. The data was shared in a spotlight discussion at the 2022 San Antonio Breast Cancer Symposium."
Clinical data
|
Myriad myRisk® Hereditary Cancer
over1year
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment (Myriad Genetics Press Release)
"Myriad Genetics...announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction....Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies....Additionally, there will also be poster session (P6-01-24) about an independent EndoPredict study....The study looked at prospective long-term outcome data with EndoPredict for women with early-stage breast cancer."
Clinical data
|
BRACAnalysis CDx™ • Myriad myChoice® CDx • EndoPredict® • Myriad myRisk® Hereditary Cancer
over1year
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting (Myriad Genetics Press Release)
"Myriad Genetics, Inc...will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41st Annual National Society of Genetic Counselors (NSGC) meeting, Nov. 16-19 in Nashville, Tenn...My Risk with Risk Score, Myriad’s market-leading hereditary cancer test that offers the first polygenic breast cancer risk assessment for women of all ancestries. RiskScore delivers a personalized 5-year and lifetime risk for developing breast cancer for women who qualify for MyRisk. JCO Precision Oncology recently published a study1 that highlights the development and validation of RiskScore for women of all ancestries. The study examined data from more than 275,000 women of diverse ancestral backgrounds to validate the use of ancestry-informative genetic markers. Results showed the new method was more accurate for women of all ancestries."
Clinical data • Clinical
|
Myriad myRisk® Hereditary Cancer
over1year
Myriad Genetics Announces UroSuite, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information (Myriad Genetics Press Release)
"Myriad Genetics, Inc...announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care....UroSuite includes Myriad’s Prolaris® Prostate Cancer Test, MyRisk™ Hereditary Cancer Test, BRACAnalysis CDx® and Precise™ Tumor Molecular Profile Test. The combination of tests provides integrated genetic insights and makes it easier to tailor therapy and clinical trial selection for patients....'Today’s launch of UroSuite reinforces Myriad Genetics’ commitment to advancing health and well-being for all through a set of testing solutions for prostate cancer care, best-in-class support, and access to genetics and cancer specialists,' said Paul J. Diaz, president and CEO, Myriad Genetics."
Launch • Clinical
|
BRACAnalysis CDx™ • Myriad myRisk® Hereditary Cancer • Precise™ Tumor Molecular Profile Test • Prolaris®